Biotech Values

[DewDiligence]

> EMIS – On the surface, the results seem promising, in that the high dose insulin group did show a signif decrease in HbA1c.<

It did not—the metric with the 0.037 p-value was a non-standard binary-responder metric that EMIS pulled out of thin air. The mean reduction in HbA1c had a p-value >0.05 (probably a lot greater) for all three insulin doses.

You should not blame yourself for being confused, however. On first inspection, I read the PR the same way you did.

It’s fairly obvious that the PR was deliberately confusing and was released a few minutes before the market open to cause even greater bewilderment.